{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:12:13Z","timestamp":1779315133018,"version":"3.51.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"HIV Unit, Hospital Clinic-IDIBAPS"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The use of dolutegravir\/lamivudine is based on solid clinical trials; however, real-world data remain limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To provide data on the clinical use and effectiveness of dolutegravir\/lamivudine in persons with HIV in a real-world scenario.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>Retrospective, single-centre and observational study. We included all adults starting dolutegravir\/lamivudine since November 2014. We reported all demographic, virological and immunological variables at baseline and assessed effectiveness [on treatment (OT), modified ITT (mITT) and ITT in those persons who reached 6 and 12 month follow-ups (M6 and M12).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 1058 persons, 9 were treatment-naive; the final analysis included 1049 treatment-experienced people with HIV. Median (IQR) follow-up was 1 (0.3\u20131.6) years, with 81% and 63% persons reaching M6 and M12, respectively. The longest use of dolutegravir\/lamivudine was 7.4 years. Per OT, mITT and ITT, HIV-RNA\u200a&amp;lt;\u200a50 copies\/mL was 97%, 92% and 81% (M6) and 98%, 90% and 80% (M12), respectively. Females [adjusted risk ratio, aRR (95% CI): 1.69 (1.19\u20132.40)]; immediate, previous PI-based regimen [aRR (95% CI): 1.67 (1.09\u20132.56)]; and viral load (VL)\u200a\u2265\u200a50 copies\/mL at dolutegravir\/lamivudine initiation [aRR (95% CI): 3.36 (2.32\u20134.88)] were independently associated with lack of effectiveness at M12; other demographic, immunological and virological variables like previous M184V\/I substitutions or virological failure, were unrelated. Of the total, 944 (90%) continued dolutegravir\/lamivudine. The most frequent known reason for discontinuation was toxicity [48 (46%) cases].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In our real-world experience, virological suppression rates were high for treatment-experienced persons on dolutegravir\/lamivudine; however, we identified subgroups with a higher risk of lack of effectiveness at M12, who may benefit from closer follow-ups.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad189","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T21:28:05Z","timestamp":1686691685000},"page":"1955-1962","source":"Crossref","is-referenced-by-count":9,"title":["Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study"],"prefix":"10.1093","volume":"78","author":[{"given":"Adri\u00e1n","family":"Mart\u00ednez-Serra","sequence":"first","affiliation":[{"name":"Infectious Disease Department, School of Medicine, University of Barcelona , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"De Lazzari","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, School of Medicine, University of Barcelona , Barcelona , Spain"},{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic , Villarroel 170, 08036, Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leire","family":"Berrocal","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic , Villarroel 170, 08036, Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Foncillas","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, School of Medicine, University of Barcelona , Barcelona , Spain"},{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic , Villarroel 170, 08036, Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"De La Mora","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, School of Medicine, University of Barcelona , Barcelona , Spain"},{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic , Villarroel 170, 08036, Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexy","family":"Inciarte","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, School of Medicine, University of Barcelona , Barcelona , Spain"},{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic , Villarroel 170, 08036, Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n","family":"Chivite","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, School of Medicine, University of Barcelona , Barcelona , Spain"},{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic , Villarroel 170, 08036, Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gonz\u00e1lez-Cord\u00f3n","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, School of Medicine, University of Barcelona , Barcelona , Spain"},{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic , Villarroel 170, 08036, Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Mart\u00ednez-Rebollar","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, School of Medicine, University of Barcelona , Barcelona , Spain"},{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic , Villarroel 170, 08036, Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-4726","authenticated-orcid":false,"given":"Berta","family":"Torres","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, School of Medicine, University of Barcelona , Barcelona , Spain"},{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic , Villarroel 170, 08036, Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, School of Medicine, University of Barcelona , Barcelona , Spain"},{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic , Villarroel 170, 08036, Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Blanco","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, School of Medicine, University of Barcelona , Barcelona , Spain"},{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic , Villarroel 170, 08036, Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, School of Medicine, University of Barcelona , Barcelona , Spain"},{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic , Villarroel 170, 08036, Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, School of Medicine, University of Barcelona , Barcelona , Spain"},{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic , Villarroel 170, 08036, Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, School of Medicine, University of Barcelona , Barcelona , Spain"},{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic , Villarroel 170, 08036, Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"2023080202261428800_dkad189-B1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2023080202261428800_dkad189-B2","author":"European AIDS Clinical Society","year":"2022"},{"key":"2023080202261428800_dkad189-B3","author":"Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2023"},{"key":"2023080202261428800_dkad189-B4","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(21)00100-4","article-title":"Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial","volume":"8","author":"Rojas","year":"2021","journal-title":"Lancet HIV"},{"key":"2023080202261428800_dkad189-B5","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3-or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study","volume":"71","author":"Van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023080202261428800_dkad189-B6","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with HIV-1: week 48 results from the phase 3, non-inferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023080202261428800_dkad189-B7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"key":"2023080202261428800_dkad189-B8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3 noninferiority TANGO randomized trial","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023080202261428800_dkad189-B9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijantimicag.2019.09.002","article-title":"Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients","volume":"54","author":"Baldin","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2023080202261428800_dkad189-B10","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/hiv.13146","article-title":"Efficacy and durability of two- vs three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients; data from real-like ODOACRE cohort","volume":"22","author":"Fabbiani","year":"2021","journal-title":"HIV Med"},{"key":"2023080202261428800_dkad189-B11","article-title":"Adherence to and forgiveness of 3TC\/DTG in a real-world cohort","volume":"21","author":"Maggiolo","year":"2022","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2023080202261428800_dkad189-B12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/v14030524","article-title":"DOLAVI real-life study of dolutegravir plus lamivudine in naive HIV-1 patients (48 weeks)","volume":"14","author":"Hidalgo-Tenorio","year":"2022","journal-title":"Viruses"},{"key":"2023080202261428800_dkad189-B13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/10600280211038504","article-title":"Dolutegravir-based dual therapies in HIV pretreated patients: a real-life study in Madrid","volume":"56","author":"Amor-Garc\u00eda","year":"2022","journal-title":"Ann Pharmacother"},{"key":"2023080202261428800_dkad189-B14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/10600280211034176","article-title":"Effectiveness, durability, and safety of dolutegravir and lamivudine versus dolutegravir, lamivudine, and abacavir in a real-life cohort of HIV-infected adults","volume":"56","author":"Mendoza","year":"2022","journal-title":"Ann Pharmacother"},{"key":"2023080202261428800_dkad189-B15","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s40121-021-00522-7","article-title":"HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review","volume":"10","author":"Patel","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2023080202261428800_dkad189-B16","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016813","article-title":"DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients","volume":"98","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2023080202261428800_dkad189-B17","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S2666-7568(22)00063-0","article-title":"Life expectancy of people with HIV on long-term antiretroviral therapy in Europe and North America: a cohort study","volume":"3","author":"Trickey","year":"2022","journal-title":"Lancet Heal Longev"},{"key":"2023080202261428800_dkad189-B18","doi-asserted-by":"crossref","first-page":"21678","DOI":"10.7448\/IAS.20.01.21678","article-title":"Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study","volume":"20","author":"Cahn","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"2023080202261428800_dkad189-B19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dky467","article-title":"Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)","volume":"74","author":"Joly","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023080202261428800_dkad189-B20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferior","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2023080202261428800_dkad189-B21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277606","article-title":"48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-na\u00efve adults living with HIV\u202f: a multicenter real-life cohort","volume":"17","author":"Cabello-Ubeda","year":"2022","journal-title":"PLoS One"},{"key":"2023080202261428800_dkad189-B22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jgar.2022.11.010","article-title":"Real world efficacy of dolutegravir plus lamivudine in PLWH with undetectable viral load after previous failures","volume":"32","author":"Gagliardini","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2023080202261428800_dkad189-B23","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1016\/S2352-3018(21)00070-9","article-title":"Overview of SARS-CoV-2 infection in adults living with HIV","volume":"8","author":"Ambrosioni","year":"2021","journal-title":"Lancet HIV"},{"key":"2023080202261428800_dkad189-B24","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2352-3018(20)30271-X","article-title":"Primary HIV-1 infection in users of pre-exposure prophylaxis","volume":"8","author":"Ambrosioni","year":"2021","journal-title":"Lancet HIV"},{"key":"2023080202261428800_dkad189-B25","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3-or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase","volume":"71","author":"Van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023080202261428800_dkad189-B26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jgar.2022.07.022","article-title":"Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study","volume":"31","author":"Santoro","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2023080202261428800_dkad189-B27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/infdis\/jiab413","article-title":"Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients","volume":"225","author":"Palich","year":"2022","journal-title":"J Infect Dis"},{"key":"2023080202261428800_dkad189-B28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11904-018-0383-2","article-title":"Sex differences in HIV infection","volume":"15","author":"Scully","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2023080202261428800_dkad189-B29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/QCO.0000000000000033","article-title":"Optimizing antiretroviral therapy for women living with HIV","volume":"27","author":"Greig","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"2023080202261428800_dkad189-B30","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jac\/dkab481","article-title":"Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre","volume":"77","author":"Ambrosioni","year":"2022","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/8\/1955\/50967416\/dkad189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/8\/1955\/50967416\/dkad189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T02:27:56Z","timestamp":1690943276000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/8\/1955\/7197296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,6,13]]},"published-print":{"date-parts":[[2023,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad189","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,6,13]]}}}